Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment

被引：6

作者：

Carbone, Antonino ^{[1
]}

Gloghini, Annunziata ^{[2
]}

Pruneri, Giancarlo ^{[2
]}

Dolcetti, Riccardo ^{[3
]}

机构：

[1] IRCCS, Ctr Riferimento Oncol Aviano CRO, Aviano, Italy

[2] Ist Nazl Tumori Milano, Fdn IRCCS, Dept Diagnost Pathol & Lab Med, Milan, Italy

[3] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia

来源：

CANCER MEDICINE | 2019年 / 8卷 / 06期

关键词：

checkpoint blockade; classic Hodgkin lymphoma; immune escape; multiplex immunohistochemistry; resistance; tumor microenvironment; CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; SUPPRESSOR-CELLS; ANALYSIS REVEALS; STERNBERG CELLS; PHASE-II; BLOCKADE; NIVOLUMAB; REED; PEMBROLIZUMAB;

D O I：

10.1002/cam4.2168

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint-blocking antibodies have therapeutic activity against relapsed or progressive classic Hodgkin lymphoma (cHL), but Hodgkin Reed-Sternberg cells can develop resistance to this therapy via multiple mechanisms. To improve the efficacy of immune checkpoint blockade, we need a more precise understanding of the immune escape mechanisms active in individual cHL patients, and this requires a detailed characterization of immune cell populations in the tumor microenvironment. These cell-cell interactions can now be studied by multiplex immunohistochemistry coupled to digital image analysis. This method should allow the identification of actionable target molecules mediating resistance to immune checkpoint inhibitors in individual cHL patients, thereby favoring the implementation of personalized therapies.

引用

页码：3012 / 3016

页数：5

共 27 条

[1] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[2] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].

Armand, Philippe ;

Engert, Andreas ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John M. ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Shipp, Margaret A. ;

Kato, Kazunobu ;

Sumbul, Anne ;

Farsaci, Benedetto ;

Ansell, Stephen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+

[3] Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure [J].

Armand, Philippe ;

Shipp, Margaret A. ;

Ribrag, Vincent ;

Michot, Jean-Marie ;

Zinzani, Pier Luigi ;

Kuruvilla, John ;

Snyder, Ellen S. ;

Ricart, Alejandro D. ;

Balakumaran, Arun ;

Rose, Shelonitda ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) :3733-+

[4] Hodgkin Lymphoma Classification: Are We at a Crossroads? [J].

Carbone, Antonino ;

Gloghini, Annunziata .

CANCER, 2017, 123 (19) :3654-3655

[5] Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment [J].

Carbone, Antonino ;

Gloghini, Annunziata ;

Castagna, Luca ;

Santoro, Armando ;

Carlo-Stella, Carmelo .

JOURNAL OF PATHOLOGY, 2015, 237 (01) :4-13

[6] Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma [J].

Carey, Christopher D. ;

Gusenleitner, Daniel ;

Lipschitz, Mikel ;

Roemer, Margaretha G. M. ;

Stack, Edward C. ;

Gjini, Evisa ;

Hu, Xihao ;

Redd, Robert ;

Freeman, Gordon J. ;

Neuberg, Donna ;

Hodi, F. Stephen ;

Liu, Xiaole Shirley ;

Shipp, Margaret A. ;

Rodig, Scott J. .

BLOOD, 2017, 130 (22) :2420-2430

[7] Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma [J].

Chen, Robert ;

Zinzani, Pier Luigi ;

Fanale, Michelle A. ;

Armand, Philippe ;

Johnson, Nathalie A. ;

Brice, Pauline ;

Radford, John ;

Ribrag, Vincent ;

Molin, Daniel ;

Vassilakopoulos, Theodoros P. ;

Tomita, Akihiro ;

von Tresckow, Bastian ;

Shipp, Margaret A. ;

Zhang, Yinghua ;

Ricart, Alejandro D. ;

Balakumaran, Arun ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2125-+

[8] Acquired natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma [J].

Chiu, Jodi ;

Ernst, Daniel M. ;

Keating, Armand .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[9] Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy [J].

de Charette, Marie ;

Houot, Roch .

HAEMATOLOGICA, 2018, 103 (08) :1256-1268

[10] Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells [J].

De Henau, Olivier ;

Rausch, Matthew ;

Winkler, David ;

Campesato, Luis Felipe ;

Liu, Cailian ;

Hirschhorn-Cymerman, Daniel ;

Budhu, Sadna ;

Ghosh, Arnab ;

Pink, Melissa ;

Tchaicha, Jeremy ;

Douglas, Mark ;

Tibbitts, Thomas ;

Sharma, Sujata ;

Proctor, Jennifer ;

Kosmider, Nicole ;

White, Kerry ;

Stern, Howard ;

Soglia, John ;

Adams, Julian ;

Palombella, Vito J. ;

McGovern, Karen ;

Kutok, Jeffery L. ;

Wolchok, Jedd D. ;

Merghoub, Taha .

NATURE, 2016, 539 (7629) :443-447

← 1 2 3 →